# A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

> **NCT06491914** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1118 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration
- Diabetic Macular Edema

## Interventions

- **DRUG:** Aflibercept 8 mg

## Key facts

- **NCT ID:** NCT06491914
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-24
- **Primary completion:** 2025-08-26
- **Final completion:** 2027-01-07
- **Target enrollment:** 1118 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491914, "A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06491914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*